Cardiovascular

Bayer at the International Society of Thrombosis and Haemostasis (ISTH) 2017 Congress

Thousands of the world’s leading experts in thrombosis, hemostasis and vascular biology will gather in Berlin, Germany, for the ISTH 2017 Congress which runs from 8 to 13 July, 2017.

The largest international meeting of the thrombosis and hemostasis community, this high-profile event offers insights into the most recent scientific advances, updates on the latest research and discussions on how clinical applications can be best applied to improve the lives of patients around the world.

This year’s ISTH will see Bayer present new data from its thrombosis and hemophilia portfolios highlighting our ongoing focus on the challenges facing both physicians and patients by addressing the unmet needs.

Dr Frank Misselwitz, Vice President and Head Therapeutic Areas Thrombosis & Hematology, Bayer, Germany
Dr Frank Misselwitz, Vice President and Head Therapeutic Areas Thrombosis & Hematology, Bayer, Germany

“ISTH offers an excellent platform to discuss the latest clinical research aimed at improving the outcomes of patients around the world in a collaborative and inspiring environment. We anticipate significant interest in Bayer’s data presentations in these areas, leading to engaging debate and discussion.”

Dr Frank Misselwitz, Vice President and Head Therapeutic Areas Thrombosis & Hematology, Bayer, Germany


Dr Jörg Möller, Member of the Executive Committee of Bayer AG's Pharmaceutical Division and Head of Development, Bayer, Germany
Dr Jörg Möller, Member of the Executive Committee of Bayer AG's Pharmaceutical Division and Head of Development, Bayer, Germany

“This year’s congress is a great opportunity to showcase our continued commitment to people with thrombotic diseases and hemophilia A. We look forward to the scientific exchange and to hear about the latest updates from key experts in the field.”

Dr Jörg Möller, Member of the Executive Committee of Bayer AG's Pharmaceutical Division and Head of Development, Bayer, Germany


Professor Jeffrey Weitz, Professor of Medicine and Biochemistry and Biomedical Sciences, McMaster University, and Executive Director of the Thrombosis and Atherosclerosis Research Institute, Hamilton, Canada
Professor Jeffrey Weitz, Professor of Medicine and Biochemistry and Biomedical Sciences, McMaster University, and Executive Director of the Thrombosis and Atherosclerosis Research Institute, Hamilton, Canada

“I am looking forward to presenting and discussing additional insights into the possibility of extended treatment with anticoagulants for people at risk of a recurrent venous thromboembolism.”

Professor Jeffrey Weitz, Professor of Medicine and Biochemistry and Biomedical Sciences, McMaster University, and Executive Director of the Thrombosis and Atherosclerosis Research Institute, Hamilton, Canada


Dr Snejana Krassova, Head of Medical Affairs, Hematology, Bayer, Switzerland
Dr Snejana Krassova, Head of Medical Affairs, Hematology, Bayer, Switzerland

People with hemophilia deserve to lead active lifestyles they choose to. Data to be announced at ISTH will contribute to the discussion around this topic as well identifying patients who could benefit from less frequent dosing whilst managing their condition. The team at Bayer is dedicated to researching novel and improved treatment options for patients as part of our long-standing commitment to hemophilia.”

Dr Snejana Krassova, Head of Medical Affairs, Hematology, Bayer, Switzerland


Professor Johannes Oldenburg, University of Bonn, Germany
Professor Johannes Oldenburg, University of Bonn, Germany

Patients living with hemophilia have been vocal about their needs in relation to prophylaxis treatment, citing fewer intravenous injections and a better quality of life as particularly important. It’s important that those with bleeding disorders maintain an active lifestyle for a healthy musculoskeletal system and at ISTH we will hear first-hand accounts of people who are living life to their full potential, regardless of their hemophilia.”

Professor Johannes Oldenburg, University of Bonn, Germany


Dr Frank Misselwitz, Vice President and Head Therapeutic Areas Thrombosis & Hematology, Bayer, Germany
Dr Frank Misselwitz, Vice President and Head Therapeutic Areas Thrombosis & Hematology, Bayer, Germany

“I was pleased to see the breadth of data presented at ISTH 2017, which demonstrates Bayer’s ongoing commitment to patients in the thrombosis and hematology space.”

Dr Frank Misselwitz, Vice President and Head Therapeutic Areas Thrombosis & Hematology, Bayer, Germany


Professor Jeffrey Weitz, Professor of Medicine and Biochemistry and Biomedical Sciences, McMaster University, and Executive Director of the Thrombosis and Atherosclerosis Research Institute, Hamilton, Canada
Professor Jeffrey Weitz, Professor of Medicine and Biochemistry and Biomedical Sciences, McMaster University, and Executive Director of the Thrombosis and Atherosclerosis Research Institute, Hamilton, Canada

“ISTH 2017 was a great opportunity to continue the discussions around additional treatment options and approaches for extending treatment in patients at risk of a recurrent venous thromboembolism.”

Professor Jeffrey Weitz, Professor of Medicine and Biochemistry and Biomedical Sciences, McMaster University, and Executive Director of the Thrombosis and Atherosclerosis Research Institute, Hamilton, Canada


Professor Johannes Oldenburg, University of Bonn, Germany
Professor Johannes Oldenburg, University of Bonn, Germany

“Being part of ISTH this year was a valuable experience as it was a great opportunity for physicians to discuss the latest advances in hemophilia treatment across the globe, learning from each other’s commitment to improving care for patients”

Professor Johannes Oldenburg, University of Bonn, Germany


Contact us

Astrid Kranz
Astrid Kranz

Head of Product Media Relations

Doreen Schröder
Doreen Schröder

Product Media Relations, Hemophilia